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Background: Post-translational modification by ubiquitin is a fundamental regulatory mechanism that is implicated
in many cellular processes including the cell cycle, apoptosis, cell adhesion, angiogenesis, and tumor growth. The
low stoichiometry of ubiquitylation presents an analytical challenge for the detection of endogenously modified
proteins in the absence of enrichment strategies. The recent availability of antibodies recognizing peptides with Lys
residues containing a di-Gly ubiquitin remnant (K-ε-GG) has greatly improved the ability to enrich and identify
ubiquitylation sites from complex protein lysates via mass spectrometry. To date, there have not been any published
studies that quantitatively assess the changes in endogenous ubiquitin-modification protein stoichiometry status at the
proteome level from different tissues.
Results: In this study, we applied an integrated quantitative mass spectrometry based approach using isobaric tags for
relative and absolute quantitation (iTRAQ) to interrogate the ubiquitin-modified proteome and the cognate global
proteome levels from luminal and basal breast cancer patient-derived xenograft tissues. Among the proteins with
quantitative global and ubiquitylation data, 91 % had unchanged levels of total protein relative abundance, and
less than 5 % of these proteins had up- or down-regulated ubiquitylation levels. Of particular note, greater than
half of the proteins with observed changes in their total protein level also had up- or down-regulated changes in
their ubiquitylation level.
Conclusions: This is the first report of the application of iTRAQ-based quantification to the integrated analysis of
the ubiquitylated and global proteomes at the tissue level. Our results underscore the importance of conducting
integrated analyses of the global and ubiquitylated proteomes toward elucidating the specific functional significance of
ubiquitylation.
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Ubiquitin is a 76 amino acid, 8.5 kDa protein that is
highly conserved among eukaryotes [1–4]. Correspond-
ingly, covalent post-translational modification (PTM) by
ubiquitin entails the formation of an isopeptide bond be-
tween the C-terminus of ubiquitin and the ε-amino
group of the targeted Lys residue on the substrate pro-
tein, although it is possible, but rare, for N-terminal* Correspondence: sthoma92@jhmi.edu
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unless otherwise stated.amines or Cys residues to be ubiquitylated as well [5]. Pro-
tein substrates can be mono-ubiquitylated at one or more
Lys residues or they can be poly-ubiquitylated by multiple
ubiquitin chains whereby each of the seven Lys residues of
ubiquitin can serve as a base to initiate chain formation.
Ubiquitylation regulates the localization, activity, and sta-
bility of protein substrates [3, 6] with functional conse-
quences related to protein turnover, endocytosis, immune
response, transcription, and DNA repair [7, 8].
Ubiquitylation has been implicated in the development
and progression of cancer and neurodegenerative dis-
eases [9, 10], and pharmacological inhibitors have been
developed that target the ubiquitin-proteasome system
for the treatment of cancer [11–13]. In the context ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumor-promoting pathways. Thus, the precise analysis of
ubiquitylation is required for the identification of ubiqui-
tylated substrates and components of the ubiquitylation
pathway that can serve as novel drug targets in the de-
velopment of highly selective therapeutic compounds.
For example, a recent ubiquitylome study by Theurillat
et al. analyzed changes in the ubiquitin landscape in-
duced by prostate cancer-associated mutations of an E3
ubiquitin ligase substrate-binding protein, thus providing
a framework to elucidate the tumorigenic mechanisms
linked to dysregulated ubiquitylation [14].
It has only been recently that advances in mass spec-
trometry and the peptide-based affinity enrichment of
the ubiquitylated proteome have permitted the large-
scale mapping of ubiquitylation sites [15–22]. The
peptide-based affinity enrichment of the ubiquitylated
proteome entails the use of a K-ε-GG antibody that spe-
cifically recognizes the di-Gly ubiquitin remnant that re-
mains conjugated to Lys residues on substrate proteins
following trypsin digestion [16, 22, 23]. K-ε-GG anti-
bodies do not distinguish between ubiquitin and two
ubiquitin-like proteins (UBLs) – NEDD8 and ISG15 –
that contain C-terminal di-Gly motifs that are generated
by trypsin cleavage [16]. However, for the current study,
the di-Gly-modified proteome and K-ε-GG-containing
peptides will be referred to as the ubiquitylated prote-
ome and ubiquitylated peptides, respectively.
The majority of the published studies that entail the
quantitative mass spectrometry-based analysis of ubiqui-
tylation using anti-K-ε-GG antibodies have been con-
ducted using cell lysate [16–20]. Although a study was
recently published that quantified the ubiquitin-modified
proteome regulated by transient forebrain ischemia in
mouse brain tissue using a label-free quantification
method [24], to date, there are no published studies of a
quantitative analysis to determine the changes in en-
dogenous protein ubiquitylation relative stoichiometry at
the tissue proteome level.
The analysis of the protein ubiquitylation level can
yield relevant biological insights that cannot be deter-
mined from the ubiquitylation or global protein level
alone. Prabakaran et al. proposed the concept of revers-
ible PTM as a form of information processing [25]. Be-
cause PTM substrate molecules can be either modified
or unmodified, and the entire pool of substrate mole-
cules is comprised of a mixture of both molecular states,
the relative stoichiometry of the modified state is there-
fore representative of the state of the population of the
substrate molecule. Olsen et al. illustrated this concept
in the context of phosphorylation site occupancy during
mitosis [26].
The relative stoichiometry of the modified state of the
population of substrate molecules is a function of thePTM’s “writers” and “erasers” [27]. Ubiquitylation entails
a highly regulated enzymatic cascade involving ubiquitin
activating (E1), ubiquitin conjugating (E2), and ubiquitin
ligating (E3) enzymes [6]. In addition to the E1, E2, and
E3 enzymes that are considered “writers” of ubiquityla-
tion, approximately 100 ubiquitylation “erasers” exist in
the form of deubiquitylating enzymes [28]. Hence, com-
plex enzymatic cascades regulate ubiquitylation.
Analyzing differences in relative abundance that are
specifically attributable to ubiquitylation instead of the
global protein level is an important step towards the de-
termination of the functional relevance of ubiquitylation
in the proteome of interest. Accordingly, in this study,
we used a mass spectrometry-based quantitative prote-
omic approach combined with the immunoaffinity en-
richment of di-Gly-modified peptides to quantitatively
analyze the relative stoichiometry of protein ubiquityla-
tion in breast cancer patient-derived xenograft tissues
using iTRAQ. We used basal and luminal human-in-
mouse breast cancer patient-derived xenografts as two
disparate tumor types from which we would expect to
observe quantitative differences in global protein levels
and ubiquitylation levels. Our integrated approach per-
mitted the analysis of changes in relative abundance not
only at the ubiquitylated protein level, but also at the
global protein level. To our knowledge, this study is the
first integrated quantitative mass spectrometry-based
analysis of endogenous ubiquitylation relative stoichiom-
etry in tissues.
Results and discussion
Quantitative approach to interrogate the ubiquitylated
proteome of tissues
The goal of this study was to identify up- or down-
regulated ubiquitylation sites on proteins with stable global
relative abundance in basal and luminal breast cancer
patient-derived xenograft tissue toward the characterization
of ubiquitylation sites that could be involved in biological
information processing. The xenografts were derived from
breast cancer patients with poor prognosis and treatment-
resistant disease [29]. Following protein extraction and
trypsin digestion, peptides from each breast cancer patient-
derived xenograft tumor tissue sample (two basal and two
luminal xenograft tissue aliquots) were subjected to di-Gly
ubiquitin remnant motif (K-ε-GG) immunoaffinity enrich-
ment using an antibody that recognizes Lys residues that
are modified with a di-Gly ubiquitin remnant (K-ε-GG).
Chemical stable isotope labeling using iTRAQ was ap-
plied to enable the relative quantification of ubiquitylation
between the samples. However, because the K-ε-GG-spe-
cific antibody only recognizes unlabeled K-ε-GG-peptides,
the iTRAQ labeling of the ubiquitylated proteome was
conducted after K-ε-GG enrichment. The peptides were
labeled with iTRAQ-114 (basal xenograft 1), iTRAQ-115
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iTRAQ-117 (luminal xenograft 2) reagents from a 4-plex
iTRAQ reagent kit, and they were subjected to LC-MS/
MS analysis.
Because the primary amine group of the di-Gly ubiqui-
tin remnant on the target Lys of the substrate protein
can be modified by iTRAQ reagents, in addition to the
constant and variable modifications that were used for
peptide and protein identification for the global prote-
ome analysis, variable modifications of +258.1449 Da
(mass of iTRAQ 4-plex reagent added to di-Gly ubiquitin
remnant) and +114.0429 Da (mass of di-Gly ubiquitin
remnant) were added to Lys residues when conducting
database searches of the ubiquitylated proteome data. An-
other consideration for the analysis of the ubiquitylated
proteome data is that results from large-scale analyses of
ubiquitin modified proteomes have indicated that trypsin,
which has a strict sequence specificity [30], does not
cleave at di-Gly-modified Lys residues [20, 21]. Hence,
missed cleavage at di-Gly-modified Lys residues provides
confidence for ubiquitylation site localization [31].
The enrichment selectivity of the ubiquitylated peptides
was 80 %, as determined by the number of peptide-
spectrum matches (PSMs) of ubiquitylated peptides (357)
divided by the total number of PSMs of all identified pep-
tides (450). In the absence of immunoaffinity enrichment,
0.02 % of the identified peptides were ubiquitylated, and
only 2 ubiquitylated peptides were identified in common
with the enriched samples: 1 polyubiquitin peptide with 4
PSMs, and 1 histone H2A.J peptide with 10 PSMs (data
not shown). The remaining 8 ubiquitylated peptides iden-
tified in the global dataset were identified by 1 PSM. The
very low yield of ubiquitylated peptides in the non-
enriched samples supports the need for an enrichment
step in the mass spectrometry-based analysis of the ubi-
quitylated proteome of complex biological samples.
In the enriched dataset, the majority (99.7 %) of the
ubiquitylated peptides had a charge ≥3+, which reflects
the additional charge from the N-terminal amine on the
di-Gly adduct from the C-terminal tryptic ubiquitin
remnant. The average peptide yield after immunoaffinity
enrichment was 5 μg from an input of 3 mg of peptides.
To evaluate the reproducibility of the quantified ubi-
quitylated peptides of human origin in the luminal vs.
basal breast tumor xenograft tissues, a linear regression
analysis was conducted on the correlation of the iTRAQ
reporter ion intensities in each luminal and basal xeno-
graft tissue specimen. Ideally, the iTRAQ reporter ion
intensities associated with the same peptide from both
replicates would be nearly identical. The reproducibility
of the two replicates (Basal 1 vs. Basal 2, Fig. 1a and Lu-
minal 1 vs. Luminal 2, Fig. 1b) was assessed based on
the slope and R2 values of the linear regressions. The
slope of the linear regression fit to the basal xenograftreplicates was 0.8314, whereas the slope of the linear re-
gression fit to the luminal xenograft replicates was 0.6979.
The 0.9601 and 0.8384 R2 values of the linear regressions
of the basal and luminal replicates, respectively, indicate
acceptable reproducibility. Technical variability was fur-
ther assessed by the distribution of the RSDs of the
log2-transformed iTRAQ reporter ion intensities of the
quantified ubiquitylated peptides (Fig. 1c). The mean
iTRAQ reporter ion intensity RSDs of the basal and lu-
minal replicates were 23 % and 27 %, respectively, which
indicates the degree of technical variability of the work-
flow that we developed to quantify endogenous ubiqui-
tylation in tissue samples.
This iTRAQ-based quantitative proteomic approach to
analyze the ubiquitin-modified proteome of luminal and
basal breast tumor xenografts resulted in the identifica-
tion of 327 unique ubiquitylated peptides at a 1 % false
discovery rate and 319 unique non-ambiguously local-
ized ubiquitylation sites that were quantified across all
four samples (Additional file 1: Table S1). For each ubi-
quitylated peptide, the average iTRAQ reporter ion in-
tensity values of the luminal samples (116 and 117
labels) were divided by the average iTRAQ reporter ion in-
tensity values of the basal samples (114 and 115) and log2-
transformed. The mean ratio of these peptides was -0.004
(log2(luminal/basal)) with a standard error of 0.06 indicat-
ing that the data are approximately normally distributed.
The distribution of the relative abundance ratios of the
ubiquitylated peptides is shown in Fig. 2a.
Reflecting the mixed human and murine proteome
backgrounds of the xenograft samples, 76 % of the identi-
fied unique ubiquitylated peptides (249) were derived from
173 proteins of human origin. The identified ubiquitin-
derived poly-ubiquitylated peptides were common to Mus
musculus polyubiquitin and Homo sapiens ubiquitin-40S
ribosomal protein S27a; therefore, it could not be defini-
tively determined whether these 6 peptides were of human
or murine origin. Proteins with functions related to the
ubiquitylation machinery (E2 ubiquitin conjugating en-
zymes, E3 ubiquitin ligases, and proteasome subunits) and
ubiquitin-like modifiers (NEDD8 and SUMO 2) were
among the quantified ubiquitylated proteins.
Whereas the majority of the ubiquitylated proteins con-
tained only 1 ubiquitylation site (115 proteins), 43 proteins
contained >1 ubiquitylation site including 4 proteins that
had 5 ubiquitylation sites and 2 proteins that had 6 ubiqui-
tylation sites (Fig. 2b). Of the 43 proteins containing
multiple ubiquitylation sites, 6 contained ubiquitylation
sites that did not exhibit the same trend in relative
abundance between the basal and luminal xenografts.
For these proteins, some sites had higher levels of rela-
tive abundance in the basal samples, whereas other
sites in the same protein had higher levels of relative
abundance in the luminal samples. This result is
Fig. 1 Reproducibility of iTRAQ-based quantitative analysis of ubiquitylation in basal and luminal breast tumor xenografts. a iTRAQ reporter ion
intensities of ubiquitylated peptides from the Basal 1 vs. Basal 2 xenografts. The inset shows an enlarged region of the plot for the ubiquitylated
peptides with intensities <1.0e5. b iTRAQ reporter ion intensities of ubiquitylated peptides from the Luminal 1 vs. Luminal 2 xenografts. The inset
shows an enlarged region of the plot for the ubiquitylated peptides with intensities <1.0e5. c Distribution of RSDs (%) of the iTRAQ reporter ion
intensities of ubiquitylated peptides from Basal 1 vs. Basal 2 (black bars) and Luminal 1 vs. Luminal 2 (grey bars) xenografts
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in conferring site-specific differential modes of regula-
tion on substrate proteins [2].
Ubiquitin was among the quantified ubiquitylated pro-
teins. Six of its seven Lys residues (K6, K27, K29, K33, K48
and K63) (Additional file 1: Table S1) were quantified.
These Lys residues are known to form poly-ubiquitin
linkages, and the specific Lys residue that is involved
in the linkage confers different cellular functions on
the substrate proteins. K48 linkages are considered
canonical signals for proteasomal degradation by the
26S proteasome [32]; K63 linkages are known to be
involved in several non-proteolytic processes such as
protein sorting, NF-κB signaling, kinase activation,
and translational control [33]; and K6, K27, K29, and
K33 linkages are hypothesized to have roles in DNA
repair [34]. None of the six quantified ubiquitylation
sites were up- or down-regulated, and the global pro-
tein level of ubiquitin was stable [average (log2(lum-
inal/basal) = −0.03)].Representative peptides with up-regulated and down-
regulated ubiquitylation sites are presented in Fig. 3. Up-
regulated and down-regulated peptides were considered
as those with log2(luminal/basal) values that were greater
or less than the mean ± 2 s.d. of the distribution of the ra-
tios for each dataset. Shown in Fig. 3a is a representative
spectrum of an ubiquitylated peptide from ubiquitin-like
protein ISG15 precursor with an up-regulated ubiquityla-
tion site (K35) in the luminal compared to the basal tumor
xenografts. The di-Gly ubiquitin remnant on K35 was la-
beled with the iTRAQ reagent, and the relative abundance
ratio (log2(luminal/basal)) was 2.69. Fig. 3b is a representa-
tive MS/MS spectrum of an ubiquitylated peptide from
ATP-binding cassette sub-family E member 1 with a
down-regulated ubiquitylation site (K250) in the luminal
compared to the basal tumor xenografts. The di-Gly
ubiquitin remnant on K250 was labeled with the
iTRAQ reagent, and the relative abundance ratio
(log2(luminal/basal)) was −2.36. The cognate unmodi-
fied (non ubiquitylated) peptide with enzymatic
Fig. 2 Distribution of the quantified ubiquitylated peptides of human origin. a A total of 249 ubiquitylated peptides of human origin were quantified
with a mean relative abundance of -0.004. For each ubiquitylated peptide, the average iTRAQ reporter ion intensity values of the luminal samples
(116 and 117 labels) were divided by the average iTRAQ reporter ion intensity values of the basal samples (114 and 115) and log2-transformed.
b Number of ubiquitylated proteins vs. the number of ubiquitylation sites per protein
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proteome dataset with an average log2(luminal/basal)
relative abundance ratio of −1.03. Some of the ubiquity-
lated peptides that were not identified in their cognate
unmodified form contained di-Gly-modified Lys resi-
dues at locations in the peptide that would result in
tryptic peptides with m/z values below the mass spec-
trometer’s detection range.To evaluate the cellular distribution of the ubiquitylated
proteins, Gene Ontology (GO) cellular compartment ana-
lysis was conducted using STRAP [35]. Proteins of human
and murine origin were used for this analysis. The results
indicate that the ubiquitylated proteins were present in all
major cellular compartments, and there was a nearly equal
distribution of ubiquitylated proteins between the cyto-
plasm (19 %) and nucleus (17 %) (Fig. 4). The cellular
Fig. 3 (See legend on next page.)
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Fig. 3 Representative spectra of quantified up-regulated and down-regulated ubiquitylated peptides. a Up-regulated ubiquitylated peptide
from ubiquitin-like protein ISG15 precursor (aa30-44) with ubiquitylation of K35. The main figure shows the MS/MS spectrum and the corresponding
ion coverage of the peptide to which the spectrum was assigned. The inset shows an enlarged region of the MS/MS spectrum (113.0 – 118.0 m/z) with
the iTRAQ reporter ions. Based on the intensity of the 114.11 and 115.11 m/z (basal xenografts) and the 116.11 and 117.11 m/z (luminal xenograft)
reporter ions, the peptide was determined to be up-regulated 2.69-fold in the luminal compared to the basal tumor sample. b Down-regulated
ubiquitylated peptide from ATP-binding cassette sub-family E member 1 (aa235-252) with ubiquitylation of K250. The main figure shows the
MS/MS spectrum and the corresponding ion coverage of the peptide to which the spectrum was assigned. The inset shows an enlarged region
of the MS/MS spectrum (113.5 – 118.0 m/z) with the iTRAQ reporter ions. The peptide was determined to be down-regulated 2.36-fold in the
luminal compared to the basal tumor samples
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cates that the enrichment was not biased toward ubiquity-
lated proteins from a specific region of the cell.
Global proteome analysis yields the identification and
quantification of hormone receptor and tumor antigen
proteins commonly used to characterize luminal and
basal breast cancer subtypes
The determination of differentially regulated ubiquityla-
tion sites relies on analysis of not only the ubiquitylated
proteome, but also the global proteome. To enable the
analysis of the basal and luminal tumor xenograft global
proteomes, 5 % of each protein digest was chemically
labeled with 4-plex iTRAQ reagents 114 and 115 (basal
xenografts 1 and 2, respectively) and 116 and 117 (luminal
xenografts 1 and 2, respectively). An equivalent amount of
peptides from the four samples was combined and sub-
jected to offline bRPLC fractionation. The 96 bRPLCFig. 4 GO cellular component categorization of ubiquitylated proteinsfractions were concatenated in a non-contiguous man-
ner to yield 24 fractions. Concatenating multiple frac-
tions that have minimal overlap and cover a wide
separation window improves the effective orthogonality
of bRPLC first dimension separation to the second dimen-
sion online RPLC separation [36]. These fractions were
then subjected to LC-MS/MS analysis, which resulted in a
total of 5,416 quantified protein groups with a minimum
of two unique peptides. Reflecting the species origin of the
samples, 78 % (4,244) were Homo sapiens proteins and
22 % (1,172) were Mus musculus proteins. A total of
46,393 unique peptides were quantified, among which
46,258 were quantified across all four xenograft tumor tis-
sue samples.
The iTRAQ reporter ion intensity ratios were log2-
transformed. The mean and standard error of the protein
ratios was 0.00 ± 0.01 (Additional file 2: Table S2). The dis-
tribution of the quantified proteins of human origin is
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cibility of the global proteome analysis workflow was
assessed based on the RSD (%) of the iTRAQ reporter ion
intensities of the quantified global peptides (Fig. 5b). The
mean RSD of the iTRAQ reporter ion intensities of the
quantified global peptides from the Basal samples was
8 %, whereas the mean RSD from the Luminal samples
was 18 %. The lower RSDs of the quantified global pep-
tides compared to the ubiquitylated peptides reflect the
differences in the workflows for these two proteomes.Fig. 5 Distribution of the quantified proteins from the global analysis work
a mean relative abundance ratio of 0.00 ± 0.01, where 0.01 is the standard error
of technical process replicate reproducibility (Basal1 vs. Basal2, black bars, and Lu
reporter ion intensities of the quantified global peptidesUnlike the ubiquitylation workflow, the basal and lu-
minal tissue-derived peptides for global analysis were
combined immediately following iTRAQ labeling and
prior to bRPLC fractionation and LC-MS/MS analysis,
whereas the peptides for ubiquitylation analysis were
not combined until after digestion, enrichment, and
iTRAQ labeling.
Ubiquitin/ISG15 conjugating enzyme was the most abun-
dant protein in the luminal xenografts (log2(luminal/
basal) = 3.36). Ubiquitin/ISG15 conjugating enzyme is anflow. a A total of 4,244 proteins of human origin were quantified with
of the mean. The ratios are reported as log2(luminal/basal). b Assessment
minal1 vs. Luminal2, grey bars) based on the RSD (%) of the iTRAQ
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the activation of ubiquitin to downstream conjugation
events, thereby influencing the fate of substrate proteins.
Relative abundance is not directly related to enzymatic ac-
tivity; therefore, the higher relative abundance of Ubiqui-
tin/ISG15 conjugating enzyme in the luminal xenografts
does not necessarily indicate an overall elevation of ubi-
quitylation in these xenografts compared to the basal xe-
nografts. There are 30 members of the E2 ubiquitin-
conjugating enzyme family, 15 of which were quantified in
this study. Whereas 6 of these E2 enzymes displayed
higher levels of relative abundance in the luminal xeno-
grafts, 9 exhibited higher levels of relative abundance in
the basal xenografts. This result reflects the complexity of
ubiquitylation that is partially attributable to the sub-
strate specificity and ubiquitin linkage topologies of the
30 E2 conjugating enzymes and the >1000 E3 ligating
enzymes in the ubiquitylation enzymatic cascade.
The depth of the proteome coverage permitted the
identification and quantification of proteins that are
clinically used to stratify breast cancer subtypes [37]:
epidermal growth factor receptor isoform 1 (log2(luminal/
basal) = −1.04), cellular tumor antigen p53 (log2(luminal/
basal) = 2.06), membrane-associated progesterone receptor
component 1 (log2(luminal/basal) = −0.44), and membrane-
associated progesterone receptor component 2 (log2(lum-
inal/basal) = 0.09). The expression of progesterone recep-
tors (PR) is generally associated with luminal breast
cancers (PR+), whereas triple negative or basal-like tumors
are typically PR- [37, 38]. The quantification of PR indi-
cates that it was present in the basal and luminal xeno-
grafts. Not all basal-like tumors are triple negative, and it
has been shown that much of the clinically observable
plasticity and heterogeneity occurs within, and not across,
the major biological breast cancer subtypes [37–39].
The molecular clinical subtype information for the pa-
tients from whom the basal and luminal breast cancer
xenograft models were derived indicate that the basal
xenograft is HER2-, ER- and PR-, whereas the luminal
xenograft (luminal A subtype) is HER2-, ER+ and PR+
[29]. However, these phenotypes were validated at pas-
sage 1 (P1) for the xenografts, and the xenografts used
for this study were acquired after P32 (basal) and P33
(luminal) following extensive expansion. No actively
growing cancer has a static genome, and genetic drift is
inherent in the xenografting process. Results from a
late-exome expansion study to characterize genomic
drift in the basal patient-derived xenograft used in this
study indicated the presence of moderate genomic in-
stability determined by the detection of several single
nucleotide variations [29]. Furthermore, although the
basal and luminal xenografts were clinically character-
ized as being HER2-, Western blot data indicated low
levels of HER2 protein expression [29].Taken together, the results from our global proteomic
analysis indicate that the workflow resulted in an ad-
equate depth of coverage to permit the identification
and quantification of hormone receptor and tumor anti-
gen proteins that are typically used to classify breast
cancer subtypes.
Differences in abundance of global proteins vs.
ubiquitylated proteins suggest differential ubiquitylation
site occupancy
After analyzing the global and ubiquitylated proteomes
of the basal and luminal breast tumor xenografts, we
sought to analyze differences in relative abundance be-
tween the global protein levels and the ubiquitylation
sites on the proteins that were common to both work-
flows. For this analysis, we only focused on the proteins
of human origin. Among the 4,244 quantified proteins
of human origin from the global analysis, 128 quantified
proteins contained ubiquitylation sites that were quanti-
fied in the ubiquitylation workflow (Fig. 6a). In this set
of commonly identified proteins, 91 % (116) had un-
changed levels of total protein relative abundance. Al-
though there were 10 ubiquitylation sites on 9 proteins
with up- or down-regulated relative abundance (6 and 4
ubiquitylation sites, respectively) in the set of commonly
identified proteins, the global relative abundance levels
of 5 of these proteins were also up- or down-regulated.
Consequently, only 4 of the up- or down-regulated ubi-
quitylation sites were localized to proteins with un-
changed relative abundance (Table 1 and Fig. 6b, dashed
rectangular box). This underscores the importance of
analyzing total protein levels when determining differ-
ences in ubiquitylation relative abundance towards the
calculation of ubiquitylation site occupancy.
The down-regulated ubiquitylation sites were on
NADPH-cytochrome P450 reductase (K613; mean ubiqui-
tylated peptide RSDBasal1,Basal2; Luminal1,Luminal2 = 24 %;
cognate global peptide not detected), bifunctional 3′-
phosphoadenosine 5′-phosphosulfate synthase 1 (K194;
mean ubiquitylated peptide RSDBasal1,Basal2; Luminal1,Lum-
inal2 = 12.5 %; cognate global peptide mean RSDBasal1,Basal2;
Luminal1,Luminal2 = 8 %), and ATP-binding cassette sub-
family E member 1 (K250; mean ubiquitylated peptide
RSDBasal1,Basal2; Luminal1,Luminal2 = 10 %; cognate global pep-
tide mean RSDBasal1,Basal2; Luminal1,Luminal2 = 9.5 %). The up-
regulated ubiquitylation site was on fatty acid synthase
(K1142; mean ubiquitylated peptide RSDBasal1,Basal2; Lumi-
nal1,Luminal2 = 27 %; cognate global peptide mean RSDBasal1,-
Basal2; Luminal1,Luminal2 = 18 %). It is possible that these
differentially regulated ubiquitylation sites reflect differ-
ences between the basal and luminal breast cancer sub-
types represented in the xenografts used for this study
[40]. Additional studies with a larger sample size are re-
quired to further elucidate this possibility.
Fig. 6 Relative abundance of global proteome vs. ubiquitylated proteome. a Among the 4,244 quantified proteins of human origin from the global
analysis and the 173 quantified proteins of human origin from the ubiquitylation analysis, 128 proteins were identified in common. b Among the 128
commonly identified proteins, 116 had unchanged total relative abundance levels (dashed rectangular box). Of these 116 proteins, 1 had up-regulated
ubiquitylation levels in the luminal xenografts (red box) and 3 had down-regulated ubiquitylation levels in the luminal xenografts (green box)
Table 1 Proteins of human origin with unchanged total relative abundance levels that have up-regulated (italic text) or down-regulated
(bold text) ubiquitylation levels in the luminal vs. basal xenografts










5′-phosphosulfate synthase 1 [Homo sapiens]
46094058 Mediation of two steps in sulfate
activation pathway
−1.29 K194 (-2.44)
ATP-binding cassette sub-family E member 1
[Homo sapiens]
108773782 Transport of molecules across extra-
and intra-cellular membranes
−1.19 K250 (-2.36)
fatty acid synthase [Homo sapiens] 41872631 Catalysis of palmitate synthesis into
long-chain saturated fatty acids
0.80 K1142 (2.46)
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In summary, we conducted an integrated iTRAQ-based
quantitative proteomic analysis that enabled the interrogation
of the relationship between global protein and endogenous
ubiquitylation relative abundance using basal and luminal
breast cancer patient-derived xenograft tissue. Among the
proteins that were quantified in their global and ubiquity-
lated forms, 91 % had unchanged levels of total protein
relative abundance in the luminal vs. basal tumor xeno-
grafts. Of the proteins with unchanged levels of global rela-
tive abundance, 4 % (5) had either up- or down-regulated
ubiquitylation relative abundance levels. The proteins with
regulated ubiquitylation levels – NADPH-cytochrome
P450 reductase, bifunctional 3′-phosphoadenosine 5′-phos-
phosulfate synthase 1, ATP-binding cassette sub-family E
member 1, and fatty acid synthase – could have functional
implications in the differentiation between the breast can-
cer subtypes used for this study.
To date, there have been relatively few quantitative
studies of endogenous ubiquitylation in tissue. Although
a study using label-free quantification to analyze the ubi-
quitylated proteome of rat brain tissue was recently pub-
lished [41], to our knowledge, our study represents the
first integrated quantitative analysis of endogenous glo-
bal protein and ubiquitylation in tissue using iTRAQ la-
beling. Variations of this approach could entail the use
of metabolic stable isotope-labeling by amino acids in
cell culture (SILAC)-labeled cell lines as spike-in stan-
dards [42, 43] as opposed to chemical-based stable iso-
tope labeling. A primary benefit of using SILAC-labeled
cell lines as spike-in standards would be the potentially
decreased technical variability because the biological
samples could be combined at an early stage in the sam-
ple preparation workflow. It has been shown that the
error associated with multiple steps of sample prepar-
ation in a SILAC-based comparative experiment entail-
ing immunoaffinity enrichment can be limited to a
reasonably low level to enable optimal quantitative ac-
curacy [44].
The workflow described in our study permits the ana-
lysis of global protein and ubiquitylation site relative
abundance toward the determination of ubiquitylation
site occupancy. Our observation that 61 % of the quanti-
fied ubiquitylation sites were on proteins whose global
relative abundance levels were up- or down-regulated
underscores the importance of analyzing the modified
and unmodified forms of ubiquitylation substrates in
studies that are designed to identify ubiquitylation sites
that have potential functional significance. Regulated
ubiquitylation sites that occur on proteins whose global
levels of relative abundance are also up-or down-
regulated are sites that are not likely involved in bio-
logical information processing. Rather, it is possible
that the regulated ubiquitylation sites with functionalroles in biological information processing are those that




Dithiothreitol (DTT), 2-chloroacetamide, Tris-HCl,
EDTA, aprotinin, leupeptin, PR-619, PMSF, and LC-MS-
grade water were purchased from Sigma-Aldrich (St. Louis,
MO). Ultra-pure urea, NaCl, dimethyl pimelimidate, LC-
MS grade acetonitrile, trifluoroacetic acid (TFA), formic
acid (FA), PepClean C18 spin columns and Empore C18
solid-phase extraction disks were purchased from Thermo
Fisher Scientific (Fair Lawn, NJ). Sequencing grade modi-
fied trypsin was purchased from Promega (Madison, WI).
Sep-Pak SPE C18 cartridges (50 mg, 1 cc) were obtained
from Waters (Milford, MA). iTRAQ 4-plex reagent kits
were purchased from AB Sciex (Framingham, MA).
Tissue homogenization
Aliquots of frozen, powderized patient-derived xenograft
tumors from established basal (WHIM2, passage 32) and
luminal A (WHIM16, passage 33) breast cancer subtypes
were obtained from the Washington University Clinical
Proteomic Tumor Analysis Consortium (CPTAC) Prote-
ome Characterization Center. The xenografts were raised
subcutaneously in 8 week old NOD.Cg-PrkdcscidIl2rgtm1Wjl/
SzJ mice (Jackson Labs, Bar Harbor, Maine) as previously
described [29, 45]. All animal procedures were reviewed
and approved by the Institutional Animal Care and Use
Committee at Washington University in St. Louis, MO.
Two aliquots of xenograft tumor tissue from basal
subtype and two aliquots of xenograft tumor tissue from
luminal subtype were used. Tissues were sonicated in
denaturing buffer (8 M urea, 50 mM Tris-HCl pH 8,
150 mM NaCl, 1 mM EDTA, 50 μM PR-619, 1 mM 2-
chloroacetamide) supplemented with protease inhibitors
(2 μg/mL aprotinin, 10 μg/mL leupeptin, 1 mM PMSF).
One hundred μL denaturing buffer was added per 10 mg
tissue. Lysates were sonicated and cleared by centrifuga-
tion at 16,000 x g for 20 min at 4 °C.
Protein digestion and iTRAQ labeling
Protein concentrations were determined using the
bicinchoninic acid (BCA) protein assay (Thermo Fisher
Scientific), and 4 mg protein was used for the subsequent
steps. Cysteines were reduced with 5 mM dithiothreitol
(DTT) for 1 h at 37 °C and alkylated using 10 mM 2-
chloroacetamide for 45 min at room temperature (~23 °C)
in the dark. The alkylation was conducted using 2-
chloroacetamide as opposed to the more commonly used
alkylating reagent iodoacetamide to avoid the formation of
Lys adducts that are identical in atomic composition to
the di-Gly ubiquitin remnant [46]. After 4-fold dilution
Thomas et al. Clinical Proteomics  (2015) 12:14 Page 12 of 15with 50 mM Tris-HCl, pH 8, trypsin was added at an
enzyme-to-substrate ratio of 1:50 (wt/wt), and the diges-
tion was allowed to proceed for 4 h at 37 °C with shaking.
An additional aliquot of trypsin was added (1:50; wt/wt)
for overnight digestion at 37 °C with shaking. Protease di-
gestion was stopped by the addition of TFA to a final con-
centration of 1 %, and the digests were subsequently
desalted using 50 mg, 1 cc Sep-Pak SPE C18 cartridges
(Waters). Sep-Pak SPE C18 cartridges were conditioned
with 1 mL 100 % acetonitrile, followed by 1 mL 50 %
acetonitrile/0.1 % TFA, and equilibrated with 2 mL 0.1 %
TFA. The peptides were loaded onto the conditioned Sep-
Pak SPE C18 cartridges, washed with 3 mL 0.1 % TFA and
eluted with 0.5 mL 50 % acetonitrile/0.1 % FA. The
A280nm-based concentration of the de-salted peptide sam-
ples was determined using a NanoDrop spectrophotom-
eter (Thermo Fisher Scientific). Aliquots of each de-salted
peptide sample (75 μg) were prepared and dried in a
SpeedVac concentrator prior to iTRAQ labeling. Three
mg aliquots of each de-salted peptide sample were pre-
pared and dried by lyophilization using a vacuum freeze
dryer (Labconco) prior to K-ɛ-GG peptide enrichment.K-ε-GG peptide enrichment
The anti-K-ε-GG ubiquitin remnant motif antibody
(component of the PTMScan® ubiquitin remnant motif
kit, Cell Signaling Technology, Danvers, MA) was cross-
linked with DMP according to the procedure detailed in
[18]. Briefly, the antibody-coupled beads were washed
three times with 1 mL of 100 mM sodium bicarbonate,
pH 9. The beads were then re-suspended in 1 mL of
20 mM DMP in 100 mM sodium bicarbonate and incu-
bated for 30 min at room temperature with end-over-end
rotation. The cross-linking reaction was stopped by wash-
ing the beads twice with 1 mL of 200 mM ethanolamine,
pH 8 and incubating for 2 h at 4 °C with end-over-end ro-
tation. The cross-linked antibody was washed three times
with 1.5 mL of immunoaffinity purification (IAP) buffer
(50 mM MOPS pH 7.2, 10 mM sodium phosphate,
50 mM NaCl).
Each dried 3 mg peptide aliquot was reconstituted in
1.5 mL of IAP buffer, and approximately 35 μg of the
cross-linked anti-K-ε-GG ubiquitin remnant motif anti-
body was added to each sample followed by incubation
for 1 h at 4 °C with end-over-end rotation. The samples
were washed twice with 1.5 mL of IAP buffer followed
by three washes with PBS. Peptides were eluted by add-
ing 50 μL of 0.15 % TFA and incubating at room
temperature for 5 min. The elution procedure was re-
peated once and the eluates were combined. Peptides
were de-salted using 200 μL C18 Stage Tips [47] packed
with three C18 Empore extraction disks. De-salted pep-
tides were dried in a SpeedVac concentrator.Because the anti-K-ε-GG antibody that was used to en-
rich for ubiquitin remnant motif-containing peptides does
not recognize iTRAQ-labeled peptides, the iTRAQ labeling
of the samples for the ubiquitylation analysis was con-
ducted after anti-K-ε-GG enrichment. The iTRAQ labeling
scheme was the same as the global samples: 114 (WHIM2
– basal tumor 1: aliquot P32–16), 115 (WHIM2 – basal
tumor 2: aliquot P32–17), 116 (WHIM16 – luminal tumor
1: aliquot P33–17), and 117 (WHIM16 – luminal tumor 2:
aliquot P33–18). The iTRAQ-labeled, K-ε-GG-enriched
samples were combined, de-salted using PepClean C18 spin
columns according to the manufacturer’s instructions and
dried in a SpeedVac concentrator.
Basic reversed phase chromatography – global proteome
analysis
For the global proteome analysis, 240 μg de-salted pep-
tides were labeled with iTRAQ 4-plex 114 (WHIM2 –
basal tumor 1: 60 μg), 115 (WHIM2 – basal tumor 2:
60 μg), 116 (WHIM16 – luminal tumor 1: 60 μg), and
117 (WHIM16 – luminal tumor 2: 60 μg) reagents. Pep-
tides were dissolved in 30 μL of 0.5 M triethylammonium
bicarbonate. Seventy μL of ethanol was added to each tube
containing 1 U iTRAQ labeling reagent. After the peptides
were added to the tubes containing the respective iTRAQ
labeling reagent, the labeling reaction was allowed to
proceed for 1 h at room temperature. The labeling reac-
tion was terminated by hydrolysis of the iTRAQ reagents
with the addition of 300 μL 0.05 % TFA followed by incu-
bation at room temperature for 30 min. The peptides were
then mixed, dried in a SpeedVac concentrator and subse-
quently de-salted using a 50 mg, 1 cc Sep-Pak SPE C18
cartridge and dried again in a SpeedVac concentrator.
Approximately 100 μg of the combined iTRAQ-
labeled sample was subjected to offline basic reversed
phase liquid chromatography (bRPLC) using a 4.6 x
100 mm Zorbax Extend-1.8 μm C18 column (Agilent
Technology, Santa Clara, CA) on an Agilent 1220 Infinity
HPLC System. The solvent consisted of 10 mM ammo-
nium formate (pH 10) in water as mobile phase A and
10 mM ammonium formate in 90 % ACN (pH 10) as mo-
bile phase B. The separation gradient was set as follows:
2 % B for 10 min, 2 – 8 % B for 5 min, 8 – 35 % B for
85 min, 35 – 95 % B for 5 min, and 95 % B for 25 min.
The 96 fractions were pooled in a non-contiguous manner
into 24 fractions by combining fractions 1, 25, 49, and 73;
2, 26, 50, and 75, etc. The concatenated fractions were
dried in a SpeedVac concentrator.
LC-MS/MS analysis
Peptides were resuspended in LC solvent A (2 % aceto-
nitrile/0.1 % formic acid) and analyzed by nanoflow
LC-MS/MS using an LTQ-Orbitrap Velos Pro mass
spectrometer (Thermo Fisher Scientific) coupled online
Thomas et al. Clinical Proteomics  (2015) 12:14 Page 13 of 15to a Dionex Ultimate 3000 RSLCnano system (Thermo
Fisher Scientific) with a 75 μm x 50 cm Acclaim PepMap
RSLC 2 μm C18 separating column (Thermo Fisher
Scientific) protected by a 100 μm x 2 cm Acclaim Pep-
Map100 5 μm C18 guard column (Thermo Fisher Sci-
entific). The mobile phase flow rate was 300 nL/min
and consisted of 0.1 % formic acid in water (A) and
0.1 % formic acid in 95 % acetonitrile (B). The gradient
profile was set as follows: 2 – 22 % B for 70 min, 22 –
29 % B for 8 min, 29 – 95 % B for 4 min, and 95 % B
for 8 min. The mass spectrometer spray voltage was set
at 2.2 kV. Full scan Orbitrap spectra (AGC 1x106) were
collected from 400–1800 m/z at a resolution of 30,000
with a maximum injection time of 10 ms followed by
data-dependent HCD MS/MS (7,500 resolution, 35 %
collision energy, 0.1 ms activation time, 100 ms max-
imum injection time, 1x104 AGC) of the 10 most abun-
dant ions using an isolation width of 2.0 Th. The
minimum signal required to trigger an MS2 scan was
500, and the first mass value was fixed at 100 m/z.
Charge state screening was enabled to reject the acqui-
sition of MS/MS spectra for unassigned and singly
charged precursor ions. A dynamic exclusion duration
of 25 s was used.
MS data analysis
MS/MS spectra were searched with SEQUEST HT using
Proteome Discoverer version 1.4 (Thermo Fisher) against a
customized combined NCBI RefSeq Release 37 of
Homo sapiens and Mus musculus database with
55,415 entries (http://fenchurch.mc.vanderbilt.edu/misc/
20111201-RefSeq-Human-37-Mouse-37-Trypsin.fasta).
The precursor and fragment mass tolerances were set to
20 ppm and 0.05 Da, respectively. Enzymatic cleavage spe-
cificity was set to fully tryptic with three missed cleavages
allowed. For the global proteomic dataset, carbamido-
methylation of cysteine and iTRAQ 4-plex modification of
peptide N-termini were set as fixed modifications, and
oxidation of methionine and iTRAQ 4-plex modification
of Lys were set as variable modifications. The data were
also searched against a decoy database (reversed protein
sequences) and filtered using a 1 % false discovery rate.
Only peptides with a search engine rank of 1 and protein
groups identified by at least two unique (non-redundant)
peptide sequences were considered. Protein ratios were
normalized based on the mean ratio distribution of each
dataset.
For the ubiquitylation dataset, to account for the add-
itional amine group that is present on the –GG remnant
of the ubiquitylated peptides that could be labeled by the
iTRAQ reagent, a variable modification of +258.1449 Da
on Lys (mass of iTRAQ 4-plex reagent and two Gly resi-
dues) was included. GlyGly addition to Lys was also used
as a variable modification. Four modifications perpeptide were permitted. The data were also searched
against a decoy database (reversed protein sequences)
and filtered with a 1 % false discovery rate. Only pep-
tides with a search engine rank of 1 were considered. All
spectra that were assigned to ubiquitylated peptides were
manually validated. Di-Gly-modified Lys residues located
on peptide C-termini were considered false positive identi-
fications and were removed.
Peptide and protein quantification was based on the
iTRAQ reporter ion intensities using Proteome Discoverer
v.1.4. Only unique (non-redundant) peptide sequences
were used for protein quantification. Although methionine
residues are chemically unstable and prone to oxidation,
peptides containing these amino acids (<1 % of the ubiqui-
tylated peptides in our dataset) were not excluded from
quantification. Unless otherwise noted, all quantification
data refer to only peptides and proteins of human origin.
Ubiquitylated peptide normalization was based on the
mean ratio distribution of each dataset. Ubiquitylation
sites or proteins with relative abundance ratios greater or
less than the mean ± 2 s.d. of the distribution of ratios for
each dataset were considered to be up- or down-
regulated, respectively, in the luminal compared to the
basal breast cancer tumor xenografts.Gene ontology functional analysis
STRAP (Software for Researching Annotations of Proteins)
[35] was used to determine the distribution of Gene
Ontology cellular compartment terms in the ubiquityla-
tion dataset.Additional files
Additional file 1: Table S1. List of quantified ubiquitylated peptides from
basal and luminal breast tumor xenografts subjected to anti-di-Gly ubiquitin
remnant immunoaffinity enrichment. The log2 peptide ratio from each
replicate is an average of all the quantified peptide-spectrum matches
for a given peptide. CVs are reported for peptides quantified by >1
peptide-spectrum match. Peptides from human and murine proteins
are included.
Additional file 2: Table S2. List of quantified proteins from global
proteome analysis of basal and luminal breast tumor xenografts. Proteins
of human and murine origin are included.Abbreviations
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